Biocartis

Biocartis is an innovative molecular diagnostics company headquartered in Mechelen, Belgium. The company describes its work as developing next-generation diagnostic solutions intended to improve clinical practice for patients, clinicians, payers and the wider healthcare industry, with a focus on oncology. It is privately held; the available evidence does not identify its founder, parent company or owner. The company’s central offering is the proprietary Idylla platform. Biocartis describes Idylla as a fully automated, sample-to-result, real-time PCR molecular testing system intended to make testing actionable, easy, fast and suitable for any laboratory. The company says its tests can provide oncology molecular biomarker results in as little as three hours. Its stated rationale is that faster access to relevant cancer mutation and treatment-resistance information may help clinicians make treatment decisions, including decisions related to personalized medicine. Biocartis reports that it offers tests supporting cancers of the lung, skin, thyroid, colorectum, endometrium, blood, brain and breast. The supplied company materials also describe research into emerging biomarker uses and partnership programs with pharmaceutical, diagnostic and biomarker companies. Its vision is to enable personalized medicine for patients around the world through broader access to molecular testing. The supplied evidence does not specify the company’s sales markets, founding date, or individual test product names.

The available evidence identifies Biocartis as an innovative molecular diagnostics company based in Mechelen, Belgium, but does not establish its founding date, founders, or earlier corporate history. It describes the company as privately held and identifies its proprietary Idylla platform as the central element of its diagnostic offering. Biocartis presents Idylla as a fully automated, sample-to-result, real-time PCR molecular testing system. The platform is intended to make molecular tests easier and faster to use in local laboratories. The company’s materials contrast this aim with the complexity and hands-on demands of some molecular diagnostic workflows, as well as delays that can arise when samples are sent to specialized centers. For oncology, Biocartis says Idylla can deliver molecular biomarker results in as little as three hours. The company describes its diagnostics as supporting clinical practice, particularly in oncology, by providing information about tumor-associated biomarkers, cancer mutations and treatment resistance. It reports test coverage for lung, skin, thyroid, colorectal, endometrial, blood, brain and breast cancers. Its stated vision is to enable personalized medicine for patients around the world through universal access to molecular testing; its mission is to make that testing actionable, easy, fast and suitable for any laboratory. Biocartis also describes work to encourage research into new and emerging uses of biomarkers and says it has partnership programs with pharmaceutical, diagnostic and biomarker companies. The available evidence does not provide dated milestones for product launches, acquisitions, leadership changes or expansion. The company’s current website lists Roger Moody as Chief Executive Officer and identifies its headquarters as Mechelen, Belgium.

A privately held molecular diagnostics company focused on oncology and on making molecular testing fast, actionable, easy and suitable for any laboratory through its proprietary Idylla platform.

• Idylla platform

  A fully automated, sample-to-result, real-time PCR molecular testing system.

• Oncology molecular biomarker tests

  The company reports tests supporting lung, skin, thyroid, colorectal, endometrial, blood, brain and breast cancers.

1. 1Biocartisbiocartis.com
2. 2About Us | Biocartisbiocartis.com
3. 3Meet the Team | Biocartisbiocartis.com
4. 4Biocartis (Belgium)wikidata.org
5. 5Be the first to get news about our products! | Biocartisbiocartis.com
6. 6Immunexpress Receives CE Mark And Signs European Commercialization Partnership For SeptiCyte® RAPIDlaboratorynetwork.com